Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 5-Day NAD+ boost improve health markers? small study investigates

NCT ID NCT07336836

Knowledge-focused Sponsor: BioNADrx Holdings, Inc. Bryleos Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested whether a 5-day course of an oral NAD+ supplement (LNAD+) could raise NAD+ levels and change biological markers in 60 healthy adults aged 45-75. Participants took either the supplement or a placebo, and researchers measured NAD+ in blood cells and circulation, along with safety and metabolic effects. The goal was to gather initial data on how this supplement might affect wellness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LathMized TM NAD+ (LNAD+) dietary supplement
What this could lead to
If successful, this study could show that oral NAD+ supplements safely raise NAD+ levels and improve certain health markers, pointing toward potential benefits for aging or wellness.
What could go wrong
This is a very small, early-phase trial in healthy people, so results may not apply to broader populations or those with health conditions. The 5-day treatment period is too short to assess long-term effects or risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

60 people

The number who actually took part.

Started

Feb 2022

Finished

Jun 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: English-speaking adults in the age range between 45 and 75 years in overall self-reported good health (excluding common conditions such as hypertension, and hyperlipidemia); * Participants able to consent for themselves; * Able to commit to the study protocol, including a 7-day washout of potentially confounding substances via restriction of supplement intake; * Tolerance for repeated venous blood draws, supplement administration, and assessment schedule, tolerance for wrist-worn wearable devices well (i.e., consistent use during the day as well as at night for the duration of the study). Exclusion Criteria: * Body Mass Index (BMI) \> 35 kg/m2; * Current chronic or acute infectious diseases (e.g., hepatitis, influenza, HIV, Lyme; COVID-19 within the past two months); * Recent SARS-CoV-2 vaccine administration (within two weeks); * Current use of NAD+ supplements and precursors; * Use of systemic anti-inflammatory medications (excluding NSAIDs and acetaminophen), immunosuppressants; * Current cancer or hematologic conditions and/or cancer treatment (radiation, chemotherapy); * Type I juvenile or Type 2 diabetes mellitus; * Autoimmune disorders (multiple sclerosis, lupus, rheumatoid arthritis, psoriasis); * Inflammatory bowel disease (ulcerative colitis, Crohn's disease); * Current pregnancy; * Current substance abuse, including alcohol, but excluding nicotine and prescription medications (e.g., physician-prescribed stimulants, opiates); * Members of the same household.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Health adult subjects are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Health adult subjects Healthy participants

Contacts and locations

Locations

  • ISB Bioanalytica, Inc.

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.